137 related articles for article (PubMed ID: 8190919)
1. [Anomalies of the masticatory apparatus in beta-thalassemia. The present status after transfusion and iron-chelating therapy].
Scutellari PN; Orzincolo C; Andraghetti D; Gamberini MR
Radiol Med; 1994 Apr; 87(4):389-96. PubMed ID: 8190919
[TBL] [Abstract][Full Text] [Related]
2. [The evolutionary effects of therapy on the skeletal lesions in beta-thalassemia].
Orzincolo C; Castaldi G; Bariani L; Scutellari PN
Radiol Med; 1994 Apr; 87(4):381-8. PubMed ID: 8190918
[TBL] [Abstract][Full Text] [Related]
3. [Oromaxillofacial changes in thalassemia major].
De Mattia D; Pettini PL; Sabato V; Rubini G; Laforgia A; Schettini F
Minerva Pediatr; 1996; 48(1-2):11-20. PubMed ID: 9072660
[TBL] [Abstract][Full Text] [Related]
4. Linear growth in homozygous beta-thalassemia and beta-thalassemia/hemoglobin E patients under different treatment regimens.
Viprakasit V; Tanphaichitr VS; Mahasandana C; Assteerawatt A; Suwantol L; Veerakul G; Kankirawatana S; Pung-Amritt P; Suvatte V
J Med Assoc Thai; 2001 Jul; 84(7):929-41. PubMed ID: 11759973
[TBL] [Abstract][Full Text] [Related]
5. Desferrioxamine therapy induces clearance of iron deposits after bone marrow transplantation for thalassemia: case report.
Giardini C; La Nasa G; Contu L; Galimberti M; Polchi P; Angelucci E; Baronciani D; Barbanti I; Muretto P; Lucarelli G
Bone Marrow Transplant; 1993; 12 Suppl 1():108-10. PubMed ID: 8374548
[No Abstract] [Full Text] [Related]
6. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
Kattamis A; Kassou C; Berdousi H; Ladis V; Papassotiriou I; Kattamis C
Haematologica; 2003 Dec; 88(12):1423-5. PubMed ID: 14687998
[No Abstract] [Full Text] [Related]
7. Transfusional hemosiderosis and combined chelation therapy in sickle thalassemia.
Tsironi M; Polonifi K; Deftereos S; Farmakis D; Andriopoulos P; Moyssakis I; Aessopos A
Eur J Haematol; 2005 Oct; 75(4):355-8. PubMed ID: 16146544
[TBL] [Abstract][Full Text] [Related]
8. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
Tanphaichitr A; Kusuwan T; Limviriyakul S; Atipas S; Pooliam J; Sangpraypan T; Tanphaichitr VS; Viprakasit V
Hemoglobin; 2014; 38(5):345-50. PubMed ID: 25051423
[TBL] [Abstract][Full Text] [Related]
9. Intravenous chelation therapy during transplantation for thalassemia.
Gaziev D; Giardini C; Angelucci E; Polchi P; Galimberti M; Baronciani D; Erer B; Maiello A; Lucarelli G
Haematologica; 1995; 80(4):300-4. PubMed ID: 7590497
[TBL] [Abstract][Full Text] [Related]
10. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Magnano C; Rizzo M; Caruso V; Gerardi C; Argento C; Campisi S; Cantella F; Commendatore F; D'Ascola DG; Fidone C; Ciancio A; Galati MC; Giuffrida G; Cingari R; Giugno G; Lombardo T; Prossomariti L; Malizia R; Meo A; Roccamo G; Romeo MA; Violi P; Cianciulli P; Rigano P
Blood Cells Mol Dis; 2009; 42(3):247-51. PubMed ID: 19233692
[TBL] [Abstract][Full Text] [Related]
11. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
Wang CH; Wu KH; Tsai FJ; Peng CT; Tsai CH
Hemoglobin; 2006; 30(2):257-62. PubMed ID: 16798651
[TBL] [Abstract][Full Text] [Related]
12. Patterns of bone diseases in transfusion-dependent homozygous thalassaemia major: predominance of osteoporosis and desferrioxamine-induced bone dysplasia.
Chan YL; Pang LM; Chik KW; Cheng JC; Li CK
Pediatr Radiol; 2002 Jul; 32(7):492-7. PubMed ID: 12107582
[TBL] [Abstract][Full Text] [Related]
13. Exchange blood transfusions for the treatment of leg ulcerations in thalassemia intermedia.
Aessopos A; Kati M; Tsironi M; Polonifi E; Farmakis D
Haematologica; 2006 May; 91(5 Suppl):ECR11. PubMed ID: 16709519
[TBL] [Abstract][Full Text] [Related]
14. Desferrioxamine-induced long bone changes in thalassaemic patients - radiographic features, prevalence and relations with growth.
Chan YL; Li CK; Pang LM; Chik KW
Clin Radiol; 2000 Aug; 55(8):610-4. PubMed ID: 10964732
[TBL] [Abstract][Full Text] [Related]
15. Outcome of thalassemia treated with conventional therapy.
Borgna-Pignatti C; Zurlo MG; DeStefano P; Boffa C; DeSanctis V; DiPalma A; DiGregorio L; Melevendi C; Piga A; Sabato V
Bone Marrow Transplant; 1993; 12 Suppl 1():2-4. PubMed ID: 8374554
[No Abstract] [Full Text] [Related]
16. [Arrhythmia in thalassemia major: evaluation of iron chelating therapy by dynamic ECG].
Cavallaro L; Meo A; Busà G; Coglitore A; Sergi G; Satullo G; Donato A; Calabrò MP; Miceli M
Minerva Cardioangiol; 1993; 41(7-8):297-301. PubMed ID: 8233011
[TBL] [Abstract][Full Text] [Related]
17. Non-transferrin-bound iron during blood transfusion cycles in beta-thalassemia major.
Grosse R; Lund U; Caruso V; Fischer R; Janka GE; Magnano C; Engelhardt R; Dürken M; Nielsen P
Ann N Y Acad Sci; 2005; 1054():429-32. PubMed ID: 16339692
[TBL] [Abstract][Full Text] [Related]
18. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
Cassinerio E; Orofino N; Roghi A; Duca L; Poggiali E; Fraquelli M; Zanaboni L; Cappellini MD
Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
[TBL] [Abstract][Full Text] [Related]
19. A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
Ha SY; Mok AS; Chu WC; Raskalkar DD; Cheuk DK; Chiang AK; Ho MH; Chan GC
Hemoglobin; 2009; 33(5):323-31. PubMed ID: 19814678
[TBL] [Abstract][Full Text] [Related]
20. Combined iron chelation therapy.
Galanello R; Agus A; Campus S; Danjou F; Giardina PJ; Grady RW
Ann N Y Acad Sci; 2010 Aug; 1202():79-86. PubMed ID: 20712777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
